You are in: eMedicine Specialties > Sports Medicine > Spine Lumbosacral SpondylolysisArticle Last Updated: Jul 22, 2005AUTHOR AND EDITOR INFORMATIONAuthor: Achilles Litao, MD, Staff Physician, Department of Internal Medicine, Lincoln Medical and Mental Health Center, Cornell University Achilles Litao is a member of the following medical societies: American Academy of Pediatrics, American College of Sports Medicine, and American Medical Association Coauthor(s): John Munyak, MD, Associate Program Director, Director of Sports Medicine Education, Department of Emergency Medicine, Lincoln Medical and Mental Health Center Editors: Andrew D Perron, MD, Residency Director, Department of Emergency Medicine, Maine Medical Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Henry T Goitz, MD, Chief, Sports Medicine, Associate Professor, Department of Orthopaedic Surgery, Medical College of Ohio; Jon Whitehurst, MD, Consulting Staff, Rockford Orthopedic Associates; Wylie D Lowery Jr, MD, Associate Professor, Department of Orthopedic Surgery, George Washington University Author and Editor Disclosure Synonyms and related keywords: lumbar spondylolysis, pars interarticularis defect, spondylolisthesis, low back pain, lower back pain INTRODUCTIONBackgroundLumbar spondylolysis is a unilateral or bilateral defect of the pars interarticularis affecting one or more of the lumbar vertebrae. The term is derived from the Greek words spondylos, meaning vertebra, and lysis, meaning break or defect. Numerous hypotheses have been proposed on the etiology of spondylolysis, as follows:
However, mechanical factors are widely believed to be the cause or at least the trigger of the development of spondylolysis, especially when congenital abnormalities are present (Gans, 1998). Moreover, spondylolysis is argued to be related to the human erect posture and lumbar curve (Arriaza, 1997). Ambulation may have a role in its genesis because no known cases exist in nonambulatory patients (Smith, 1999). As an acquired condition, no reports exist of its occurrence in stillborn fetuses or in the newborn (Dubousset, 1997). Heredity is also implicated (Albanese, 1982). When the defect in the pars interarticularis is not associated with a forward displacement, the term spondylolysis applies (Stinson, 1993). Spondylolisthesis is from spondylos and listhesis, meaning movement or slipping, and refers to the slipping forward of one vertebra on the next caudal vertebra. Spondylolysis is most common at L5, accounting for 85% of all cases (Patel, 2000), and may be observed as high as L2 (Weiker, 1989). Therefore, a slip is most common at the level of L5 slipping forward on S1. Spondylolysis is the cause of the most common type of spondylolisthesis (Lonstein, 1999). Moreover, a case of spondylolysis that occurred at 3 sites in L5 involving the bilateral pars interarticularis and the center of the right lamina is reported (Ariyoshi, 1999). FrequencyUnited StatesSpondylolysis is more commonly observed in males (Patel, 2000), but this difference may not be significant (Commandre, 1998; Soler, 2000). In the United States, a reported difference exists between the sexes and races, with an incidence of spondylolysis of 6.4% in white men, 2.8% in black men, 2.3% in white women, and 1.1% in black women. Pars defect is twice as common in boys than in girls, although high-grade slippage is 4 times more common in girls than in boys. Alaskan Eskimos (26%) have the highest incidence, with the highest rate in Eskimos from north of the Yukon River (Lonstein, 1999). Functional AnatomyRepetitive axial loading, especially in an extended lumbar spine is thought to be the most important contributing mechanism, leading to fatigue fracture of the pars interarticularis. Shear stresses on the isthmic pars are greater when the lumbar spine is extended. When repetitive extension stresses occur, the pars interarticularis becomes impinged from the inferior facet of the cephalad vertebrae, which results in microfractures and attempts at repair (Congeni, 1997). Sport Specific BiomechanicsSpondylolysis occurs in 3-7% of the general population (Soler, 2000). The athletic population is believed to be more prone to the development of spondylolysis (Congeni, 1997) because its incidence in competitive athletes is higher than the percentage reported for the nonsports population (Rossi, 1990). The overall percentage of spondylolysis among athletes in a recent study is about 8%, a figure not significantly higher than that among the general population. However, certain sporting events were found to contribute higher percentages when each sport was considered separately, with the highest percentages occurring in throwing sports (26.67%), artistic gymnastics (16.96%), and rowing (16.88%) (Soler, 2000). In an earlier series, a high percentage of spondylolysis has been observed in diving (43.13%), wrestling (29.82%), and weightlifting (22.68%) (Rossi, 1990). Other sports with high incidence rates of spondylolysis are ballet, dancing, football, volleyball, and fast bowlers in cricket. In ballet, the higher incidence rate is due in part to an inability to reach or maintain proper turn-out and thus overcompensation with lordosis. In general, the presence of the repetitive actions of flexion, extension, rotation, and torsion, either alone or in combination, that are often associated with resistance are the biomechanical movements that show the highest prevalence of spondylolysis (Soler, 2000). CLINICALHistory
Physical
Causes
DIFFERENTIALSLumbosacral Disc Injuries Lumbosacral Discogenic Pain Syndrome Lumbosacral Facet Syndrome Lumbosacral Spine Acute Bony Injuries Lumbosacral Spine Sprain/Strain Injuries Lumbosacral Spondylolisthesis Lumbosacral Spondylolysis Myofascial Pain in Athletes Sacroiliac Joint Injury
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Acetaminophen (Tylenol, Feverall, Aspirin-Free Anacin) |
|---|---|
| Description | Effective analgesic-antipyretic but only has weak anti-inflammatory effects. Inhibits prostaglandin synthetase. Well absorbed from gastrointestinal tract. Peak concentrations in serum are reached within 2 h. |
| Adult Dose | 500-1000 mg q4h PO prn for pain |
| Pediatric Dose | 10-15 mg/kg q4h PO prn for pain; not to exceed adult dose |
| Contraindications | Documented hypersensitivity; known G-6-PD deficiency |
| Interactions | Rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Hepatotoxicity is possible in people with long-term alcoholism following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; APAP is contained in many OTC products, and combined use with these products may result in cumulative APAP doses exceeding recommended maximum dose |
| Drug Name | Acetaminophen and codeine (Tylenol #3) |
|---|---|
| Description | Indicated for the treatment of mild to moderate pain. |
| Adult Dose | 30-60 mg/dose PO based on codeine content q4-6h or 1-2 tab q4h; not to exceed 4 g/d of acetaminophen |
| Pediatric Dose | 0.5-1 mg/kg/dose PO based on codeine q4-6h; 10-15 mg/kg/dose based on acetaminophen content; not to exceed 2.6 g/d of acetaminophen |
| Contraindications | Documented hypersensitivity |
| Interactions | Toxicity of codeine increases with CNS depressants, tricyclic antidepressants, MAOIs, neuromuscular blockers, CNS depressants, phenothiazines, and narcotic analgesics Rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity of acetaminophen |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in patients dependent on opiates because this substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction Hepatotoxicity with acetaminophen possible in people with long-term alcoholism following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; acetaminophen is contained in many OTC products, and combined use with these products may result in cumulative acetaminophen doses exceeding recommended maximum dose |
| Drug Name | Hydrocodone and acetaminophen (Lortab, Lorcet-HD, Vicodin, Norcet) |
|---|---|
| Description | Drug combination indicated for moderate to severe pain. Available in different strengths. |
| Adult Dose | 1-2 tab PO q4-6h; not to exceed 4 g/d of acetaminophen |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose acetaminophen PO q4-6h prn; not to exceed 2.6 g/d acetaminophen >12 years: 750 mg acetaminophen PO q4h; not to exceed 10 mg hydrocodone bitartrate per dose or 5 doses/24 h |
| Contraindications | Documented hypersensitivity to hydrocodone, acetaminophen or components; high altitude cerebral edema (HACE) or elevated intracranial pressure (ICP) |
| Interactions | Coadministration with phenothiazines may decrease analgesic effects; toxicity increases with CNS depressants or tricyclic antidepressants |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Tabs contain metabisulfite, which may cause hypersensitivity; caution in patients dependent on opiates because this substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction; tolerance or drug dependence may result from prolonged use |
| Drug Name | Hydrocodone and ibuprofen (Vicoprofen) |
|---|---|
| Description | Drug combination indicated for short-term (<10 d) relief of moderate to severe acute pain. |
| Adult Dose | 1-2 tab PO q4-6h prn pain; not to exceed 5 tab/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; third trimester of pregnancy |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in impaired renal function, peptic ulcer disease, impaired thyroid function, asthma, hypertension, edema, heart failure, increased intracranial pressure, and erosive gastritis; duration of action may increase in elderly patients |
| Drug Name | Propoxyphene and acetaminophen (Darvocet-N100, Wygesic) |
|---|---|
| Description | Drug combination indicated for mild to moderate pain. |
| Adult Dose | 1-2 tab PO q4h prn; not to exceed 600 mg/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | May increase serum concentrations of MAOIs, tricyclic antidepressants, carbamazepine, phenobarbital, and warfarin |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in patients dependent on opiates because substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction |
Have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known, but they may inhibit cyclooxygenase (COX) activity and prostaglandin synthesis. Other mechanisms may exist as well, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell-membrane functions.
| Drug Name | Naproxen (Anaprox, Naprelan, Naprosyn, Aleve) |
|---|---|
| Description | For relief of mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing activity of COX, which results in a decrease of prostaglandin synthesis. |
| Adult Dose | 500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d |
| Pediatric Dose | <2 years: Not established >2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
| Drug Name | Ibuprofen (Motrin, Ibuprin, Advil) |
|---|---|
| Description | NSAIDS exert their main therapeutic effect on pain and inflammation principally by inhibition of prostaglandin synthesis. |
| Adult Dose | 400 mg q4-6h prn mild to moderate pain |
| Pediatric Dose | 10 mg/kg q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | May decrease anti-hypertensive effect of angiotensin-converting enzyme (ACE) inhibitors; can reduce the natriuretic effect of furosemide and thiazides in some patients; reduces lithium clearance |
| Pregnancy | B - Usually safe but benefits must outweigh the risks |
| Precautions | Use of NSAIDS is not recommended during pregnancy, labor, and delivery and in nursing mothers; use of NSAIDS may result in or aggravate gastrointestinal adverse effects and bleeding and cause hypersensitivity reactions |
| Drug Name | Mefenamic acid (Ponstel) |
|---|---|
| Description | Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis. |
| Adult Dose | 500 mg PO initially then 250 mg q6h prn for not more than 1 wk |
| Pediatric Dose | <14 years: Not established >14 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in third trimester of pregnancy; may have adverse effects in fetus; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy |
| Drug Name | Ketoprofen (Orudis, Oruvail, Actron) |
|---|---|
| Description | For relief of mild to moderate pain and inflammation. Small dosages are initially indicated in small and elderly patients and in those with renal or liver disease. Doses >75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe patient for response. |
| Adult Dose | 25-50 mg PO q6-8h prn; not to exceed 300 mg/d |
| Pediatric Dose | 3 months to 12 years: 0.1-1 mg/kg PO q6-8h >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Rofecoxib (Vioxx) |
|---|---|
| Description | On September 30, 2004, Merck & Co, Inc, announced a voluntary withdrawal of rofecoxib (Vioxx) from the US and worldwide market because of its association with an increased rate of cardiovascular events (including heart attacks and strokes) compared to that of placebo. Inhibits primarily COX-2. COX-2 is considered an inducible isoenzyme induced during pain and inflammatory stimuli. Inhibition of COX-1 may contribute to NSAID GI toxicity. At therapeutic concentrations, COX-1 isoenzyme is not inhibited, thus GI toxicity may be decreased. Seek lowest dose of rofecoxib for each patient.The susp dose, 12.5 mg/5 mL or 25 mg/5 mL, may be substituted for 12.5- or 25-mg tabs, respectively. |
| Adult Dose | 50 mg PO qd; subsequent doses are 50 mg qd prn; use for >5 d in management of pain not established; tabs may be taken with or without food |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with fluconazole may cause increase in rofecoxib plasma concentrations because of inhibition of rofecoxib metabolism; coadministration of rofecoxib with rifampin may decrease rofecoxib plasma concentrations |
| Pregnancy | B - Usually safe but benefits must outweigh the risks |
| Precautions | May cause fluid retention and peripheral edema; caution in compromised cardiac function, hypertension, and conditions predisposing to fluid retention; caution in severe heart failure and hyponatremia because may deteriorate circulatory hemodynamics; NSAIDs may mask usual signs of infection; caution in the presence of existing controlled infections; evaluate therapy when symptoms or laboratory results suggest liver dysfunction Alert: On September 30, 2004, Merck & Co, Inc, announced a voluntary withdrawal of rofecoxib (Vioxx) from the US and worldwide market because of its association with an increased rate of cardiovascular events (including heart attacks and strokes) compared to that of placebo. A major FDA study of rofecoxib found an apparent 3-fold increase in the risk of sudden cardiac death or heart attack among patients who had taken higher doses of the drug compared to the risk of patients who had not recently received similar medication. The report showed that even patients taking the standard starting dose of 12.5 mg or 25 mg of rofecoxib had a 50% greater chance of heart attack or sudden cardiac death than patients on any dose of celecoxib (Celebrex). The large-scale study was conducted after analyzing the medical records of 1.4 million people insured by Kaiser Permanente in Oakland, Calif, between 1999-2001. Note: The study has inherent limitations in that it is observational, rather than randomized and controlled. |
| Drug Name | Valdecoxib (Bextra) |
|---|---|
| Description | Alert: On April 7, 2005, valdecoxib (Bextra, by Pfizer, Inc) was voluntarily withdrawn from the US market, pending further discussion with the US Food and Drug Administration (FDA). The association of valdecoxib with potentially life-threatening risks, including myocardial infarction, stroke, and serious skin reactions, initiated an investigation to determine whether the benefits of the drug outweighed the risks. Second-generation COX-2 inhibitor that offers a very rapid onset and prolonged efficacy. Inhibits primarily COX-2. COX-2 is considered an inducible isoenzyme induced during pain and inflammatory stimuli. Inhibition of COX-1 may contribute to NSAID GI toxicity. At therapeutic concentrations, valdecoxib does not inhibit COX-1 isoenzyme, decreasing GI toxicity. |
| Adult Dose | 10 mg PO qd |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with fluconazole may increase valdecoxib plasma concentrations; coadministration with rifampin may decrease valdecoxib plasma concentrations |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in third trimester of pregnancy; abdominal pain, nausea, and diarrhea may occur; caution in compromised cardiac function, hypertension, and conditions predisposing to fluid retention; caution in severe heart failure and hyponatremia because may deteriorate circulatory hemodynamics; NSAIDs may mask usual signs of infection; caution in the presence of existing controlled infections; evaluate therapy when symptoms or laboratory results suggest liver dysfunction Alert: On April 7, 2005, valdecoxib (Bextra, by Pfizer, Inc) was voluntarily withdrawn from the US market, pending further discussion with the US Food and Drug Administration (FDA). The association of valdecoxib with potentially life-threatening risks, including myocardial infarction, stroke, and serious skin reactions, initiated an investigation to determine whether the benefits of the drug outweighed the risks. In 2004, the FDA had Pfizer add a boxed, bolded warning to the prescribing information to alert health care professionals and patients about the serious adverse effects. Serious, potentially fatal skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, may occur. These reactions are most likely to happen in the first 2 weeks of treatment, but they can occur any time during therapy. Valdecoxib should be discontinued at the first sign of rash, mouth sores, and/or allergic reaction (eg, swelling, itching, shortness of breath). Other COX-2 inhibitors (eg, rofecoxib [Vioxx], celecoxib [Celebrex]) and traditional NSAIDs (eg, naproxen [Aleve, Naprosyn], ibuprofen [Motrin]) also have a risk for these rare, serious skin reactions, but the reported rate of the reactions appears to be greater for valdecoxib. New data regarding cardiovascular risks are also highlighted, including data from more than 1500 patients treated after CABG. The patients treated with valdecoxib showed an increased cardiovascular risk compared to those treated with placebos. Observed cardiovascular events included myocardial infarction, cerebrovascular accident, deep vein thrombosis, and pulmonary embolism. Pfizer submitted the final report of the new CABG study to the FDA on November 5, 2004. The report confirms the risk of the intravenous form (~2% of patients experienced adverse cardiovascular events) and also shows that oral valdecoxib is associated with a lower risk (~1% of patients) immediately following CABG surgery. In the placebo group, about 0.5% of patients had an adverse cardiovascular event. |
| Drug Name | Celecoxib (Celebrex) |
|---|---|
| Description | Inhibits primarily COX-2. COX-2 is considered an inducible isoenzyme induced during pain and inflammatory stimuli. Inhibition of COX-1 may contribute to NSAID GI toxicity. At therapeutic concentrations, COX-1 isoenzyme is not inhibited, thus GI toxicity may be decreased. Seek lowest dose of celecoxib for each patient. |
| Adult Dose | 200 mg/d PO qd; alternatively, 100 mg PO bid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with fluconazole may increase celecoxib plasma concentrations because of inhibition of celecoxib metabolism; coadministration with rifampin may decrease celecoxib plasma concentrations |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; may cause fluid retention and peripheral edema; caution in compromised cardiac function, hypertension, and conditions predisposing to fluid retention; caution in severe heart failure and hyponatremia because may deteriorate circulatory hemodynamics; NSAIDs may mask usual signs of infection; caution in the presence of existing controlled infections; evaluate therapy when symptoms or laboratory results suggest liver dysfunction |
Muscle relaxants are overprescribed and have not been demonstrated to be of significant help.
| Drug Name | Methocarbamol/aspirin |
|---|---|
| Description | Used mainly as adjunctive treatment of muscle spasm associated with acute painful musculoskeletal conditions. It causes musculoskeletal relaxation by decreasing impulse transmission from the spinal cord to the muscle. |
| Adult Dose | 2 tabs qid |
| Pediatric Dose | >12 years: 2 tabs qid |
| Contraindications | Documented hypersensitivity |
| Interactions | Increased toxicity with CNS depressants; aspirin blunts antihypertensive effect of ACE inhibitors |
| Pregnancy | C - Safety for use during pregnancy has not been established |
| Precautions | Avoid in patients with underlying bleeding and platelet disorders (increases risk of bleeding), peptic ulcer disease, and renal dysfunction |
Return to play is first begun with low-level sport activities after the follow-up visit at 4-6 weeks, after which gradual increase in intensity as tolerated is allowed under supervision (Moeller, 2001). Return to full activity is permitted only when patients are totally asymptomatic with full range of motion (Weiker, 1989). Patients must also have normal flexibility and normal strength and balance.
Complications include a progression to spondylolisthesis (ie, slippage of the vertebrae and its sequelae) as well as delayed diagnosis and nonunion with chronic pain.
Because the etiology is unknown and factors that cause slippage are unknown, prevention suggestions are unavailable. However, athletes must be advised that preventing recurrences may prove difficult if they return to high-level competition.
If treatment is instituted early, lumbar spondylolysis can be successfully treated with conservative management (Morita, 1995). The cure rate for early spondylolysis with activity restriction and a thoracolumbosacral orthosis is 73%, while more advanced spondylolyses were found to be less responsive to this regimen (Morita, 1995).
With history and physical examination findings compatible with spondylolysis, athletes with normal findings on plain radiography and bone scanning are most likely to have pathology other than a pars defect. They are presumed to have a chronic back strain, and further investigation of the cause of the back pain is indicated while they are placed on physical therapy. Studies are repeated in 6-8 weeks if patients are still symptomatic with physical therapy (Weiker, 1989). MRI is appropriate in this setting (Dutton, 2000).
Surgical treatment is an option for persistently symptomatic patients who did not achieve bony healing with activity restriction and bracing (Buck, 1970; Morscher, 1984; Scott, 1987; Kakiuchi, 1997; Wu, 1999; Chen, 2000; De Gauzy, 2000). Bony union has also been reported with transcutaneous electrical stimulation in this group of patients (Fellander-Tsai, 1998).
All athletes, especially those younger than 18 years, should know that not all sources of back pain are muscular and, therefore, should not be ignored if persistent. This is most important if the athlete is participating in gymnastics, football, dancing, or figure skating.
For excellent patient education resources, visit eMedicine's Back, Ribs, Neck, and Head Center. Also, see eMedicine's patient education article Back Pain.
| Media file 1: Lumbosacral spondylolysis. Radiograph of L4 defect in the pars interarticularis. | |
![]() | View Full Size Image | Media type: X-RAY |
| Media file 2: Lumbosacral spondylolysis. CT scan demonstrating defects in the left and right pars interarticularis. | |
![]() | View Full Size Image | Media type: CT |
Lumbosacral Spondylolysis excerpt
Article Last Updated: Jul 22, 2005